CA3265264A1 - Anticorps anti-ccr8 et leurs utilisations - Google Patents

Anticorps anti-ccr8 et leurs utilisations

Info

Publication number
CA3265264A1
CA3265264A1 CA3265264A CA3265264A CA3265264A1 CA 3265264 A1 CA3265264 A1 CA 3265264A1 CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A CA3265264 A CA 3265264A CA 3265264 A1 CA3265264 A1 CA 3265264A1
Authority
CA
Canada
Prior art keywords
ccr8 antibodies
ccr8
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3265264A
Other languages
English (en)
Inventor
David T. BROUSSEAU
Gail Walkinshaw
Claudia Witschi
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of CA3265264A1 publication Critical patent/CA3265264A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3265264A 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations Pending CA3265264A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263399483P 2022-08-19 2022-08-19
US63/399,483 2022-08-19
PCT/US2023/072462 WO2024040216A2 (fr) 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3265264A1 true CA3265264A1 (fr) 2024-02-22

Family

ID=88020873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3265264A Pending CA3265264A1 (fr) 2022-08-19 2023-08-18 Anticorps anti-ccr8 et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4573126A2 (fr)
JP (1) JP2025527535A (fr)
KR (1) KR20250052418A (fr)
CN (1) CN120051493A (fr)
AU (1) AU2023325323A1 (fr)
CA (1) CA3265264A1 (fr)
WO (1) WO2024040216A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024248037A1 (fr) 2023-05-30 2024-12-05 塩野義製薬株式会社 Anticorps bispécifique qui reconnaît ccr8 en tant qu'antigène
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
CN121779523A (zh) * 2026-03-05 2026-04-03 山东中医药大学 一种鳗草来源的多肽及其提升岩藻糖含量的应用
CN122127453A (zh) * 2026-04-20 2026-06-02 广州国家实验室 一种抗呼吸道合胞病毒的单克隆抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
WO2006076288A2 (fr) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Constructions d'adn pour l'expression a long terme d'adn nu en injection intravasculaire
AU2021205877B2 (en) * 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021244200A1 (en) * 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
EP4267617A1 (fr) * 2020-12-24 2023-11-01 Vib Vzw Liants ccr8 humains
JP2024531409A (ja) 2021-08-20 2024-08-29 ハイファイバイオ， インコーポレイテッド 抗ｃｃｒ８抗体およびその使用

Also Published As

Publication number Publication date
WO2024040216A2 (fr) 2024-02-22
KR20250052418A (ko) 2025-04-18
CN120051493A (zh) 2025-05-27
WO2024040216A3 (fr) 2024-04-11
JP2025527535A (ja) 2025-08-22
EP4573126A2 (fr) 2025-06-25
AU2023325323A1 (en) 2025-03-27

Similar Documents

Publication Publication Date Title
CA3266237A1 (fr) Anticorps anti-sars-cov2 et leurs utilisations
CA3254156A1 (fr) Anticorps anti-cd84 et leurs utilisations
CA3260932A1 (fr) Anticorps spécifiques de cd25 et leurs utilisations
CA3310135A1 (fr) Anticorps ciblant cd40 et leurs utilisations
CA3306831A1 (fr) ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS
CA3307613A1 (fr) Anticorps anti-ny-eso-1 et leurs utilisations
CA3307647A1 (fr) Anticorps anti-il-4 ra et leurs utilisations
CA3304852A1 (fr) Anticorps anti-tigit et leurs utilisations
CA3305834A1 (fr) Anticorps anti-cdh17 et leurs utilisations
CA3304830A1 (fr) Anticorps anti-tdp-43 et leurs utilisations
CA3303332A1 (fr) Anticorps anti-ly6 et leurs utilisations
CA3299540A1 (fr) Anticorps anti-b7-h3 et leurs utilisations
CA3299545A1 (fr) Anticorps anti-acvr2b et leurs utilisations
CA3296337A1 (fr) Anticorps anti-klrg1 et leurs utilisations
AU2024312447A1 (en) Anti-klrg1 antibodies and uses thereof
CA3296478A1 (fr) Anticorps et leurs utilisations
CA3294517A1 (fr) Anticorps anti-tigit et leurs utilisations
CA3294500A1 (fr) Anticorps anti-pvrig et leurs utilisations
CA3291454A1 (fr) Anticorps et leurs utilisations
CA3292497A1 (fr) Anticorps et leurs utilisations
CA3291547A1 (fr) Anticorps ciblant bdca2 et leurs utilisations
CA3284726A1 (fr) Anticorps anti-tmprss6 et leurs utilisations
CA3291293A1 (fr) Anticorps anti-cd16a et leurs utilisations
CA3284328A1 (fr) Anticorps et leurs utilisations
CA3284518A1 (fr) Anticorps ciblant ilt7 et leurs utilisations

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250520

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250520

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250521

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250521